XOMA to Present at the Piper Jaffray Healthcare Conference

BERKELEY, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA, a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the company's Chief Executive Officer, is scheduled to present at the 25^th Annual Piper Jaffray Healthcare Conference on December 4, 2013, at 2:00 p.m. EST, at The New York Palace Hotel.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.

About XOMA Corporation

XOMA's portfolio of innovative product candidates is the result of the Company's focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.

More detailed information can be found at www.xoma.com.